This article is more than 5 years old. Information may no longer be current.

Choroidal melanoma treatment shows promising early results in phase 1b/2 trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Light-activated AU-011 for the treatment of primary choroidal melanoma was well tolerated with no severe adverse events, while showing promising early efficacy results, in a phase 1b/2 trial, Aura Biosciences announced in a press release.

The open-label, multicenter trial is evaluating the safety and efficacy of single and multiple ascending doses of AU-011 in 30 adult patients with small to medium primary choroidal melanoma.

Interim data showed two subjects in the first multiple-ascending-dose cohort had evidence of tumor reduction after 3 months, the release said. In addition, subtherapeutic doses in the single-ascending-dose cohorts had stable disease with vision preservation up to 12 months, and pretreatment visual acuity was maintained in all subjects who had been followed for 6 to 12 months.

“These findings indicate that Aura’s novel, targeted, light-activated treatment could hold real promise for patients with choroidal melanoma,” Cadmus Rich, MD, Aura’s chief medical officer, said in the release.